The peptides studied for amplifying the body's natural growth-hormone pulse — GHRH analogs and GHRPs — grouped so you can see how they differ and where the research stands. Every claim is sourced on each peptide's own guide.
Growth-hormone secretagogues are studied for amplifying the body's own growth-hormone pulse — releasing GH from the pituitary rather than introducing it directly. The research interest is in body composition, recovery, and the age-related decline in GH, using GHRH analogs and GHRPs (growth-hormone releasing peptides).
These are distinct from recombinant human growth hormone itself; they rely on the body's natural feedback loops, which researchers see as a safety advantage. Most of this group is research-grade, with one notable approved exception.
GHRH analog studied for growth-hormone pulse amplification and IGF-1.
GHRP studied for growth-hormone release with comparatively mild gastric effects.
GHRH analog researched for visceral-adipose outcomes in specific populations.
Tesamorelin is FDA-approved specifically for HIV-associated lipodystrophy (excess visceral fat) and is the only member here with that regulatory status. CJC-1295 (a GHRH analog) and ipamorelin (a GHRP) are research compounds that are frequently stacked because each targets a different part of the GH-release pathway — the analog extends the pulse while the GHRP amplifies it.
Published human data on the stacked research compounds is limited, so the framing stays on what's documented rather than on bodybuilding dosing lore.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.